Cargando…

Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature

TP53 is the most frequently mutated gene in muscle invasive bladder cancer (MIBC) and there are two gene signatures regarding TP53 developed for MIBC prognosis. However, they are limited to immune genes only and unable to be used individually across platforms due to their quantitative manners. We us...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Hua-Ping, Jia, Wei, Kadeerhan, Gaohaer, Xue, Bo, Guo, Wenmin, Niu, Lu, Wang, Xiaoliang, Wu, Xiaolin, Li, Haitao, Tian, Jun, Wang, Dongwen, Lai, Hung-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873666/ https://www.ncbi.nlm.nih.gov/pubmed/36689862 http://dx.doi.org/10.1016/j.tranon.2023.101629

Ejemplares similares

TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics study
por: Tao, Yuting, et al.
Publicado: (2022)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Incidence trends and survival of metastatic prostate cancer with bone and visceral involvement: 2010-2019 surveillance, epidemiology, and end results
por: Kadeerhan, Gaohaer, et al.
Publicado: (2023)

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
por: Guo, Chunguang, et al.
Publicado: (2022)

Significance of TP53 Mutational Status-Associated Signature in the Progression and Prognosis of Endometrial Carcinoma
por: Chen, Ying, et al.
Publicado: (2022)

Alcohol dehydrogenase 4 is a TP53-associated gene signature for the prediction of prognosis in hepatocellular carcinoma
por: Zhang, Yuan, et al.
Publicado: (2022)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
por: Abdel-Fattah, R., et al.
Publicado: (1998)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis
por: Yang, Y C, et al.
Publicado: (2006)

The TP53-Related Signature Predicts Immune Cell Infiltration, Therapeutic Response, and Prognosis in Patients With Esophageal Carcinoma
por: Zhang, Hongpan, et al.
Publicado: (2021)

TP53 variants in p53 signatures and the clonality of STICs in RRSO samples
por: Akahane, Tomoko, et al.
Publicado: (2022)

TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer
por: Zhang, Feng, et al.
Publicado: (2021)

Deletions of 9p21 and TP53 in bladder cancer.
por: Park, W. S., et al.
Publicado: (1996)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

Signatures of Synchrony in Pairwise Count Correlations
por: Tchumatchenko, Tatjana, et al.
Publicado: (2010)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
por: Wu, Guang, et al.
Publicado: (2019)

A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer
por: Wu, Xiangkun, et al.
Publicado: (2020)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma
por: Xu, Feng, et al.
Publicado: (2020)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
por: Flynt, Erin, et al.
Publicado: (2020)

TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma
por: Khan, Safir Ullah, et al.
Publicado: (2023)

Prognosis stratification and personalized treatment in bladder cancer through a robust immune gene pair‐based signature
por: Lu, Xiaofan, et al.
Publicado: (2021)

Association between metabolically healthy obesity and kidney stones: results from the 2011–2018 National Health and Nutrition Examination Survey
por: Chen, Weinan, et al.
Publicado: (2023)

P1155: MORE PRECISE RISK STRATIFICATION FOR TP53 MUTANT DIFFUSE LARGE B CELL LYMPHOMA
por: Du, Kai-Xin, et al.
Publicado: (2023)

A novel strategy for precise prognosis management and treatment option in colon adenocarcinoma with TP53 mutations
por: Niu, Lei, et al.
Publicado: (2023)

The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta‐analysis
por: Liao, Yihao, et al.
Publicado: (2021)

TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
por: Maschietto, Mariana, et al.
Publicado: (2014)

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
por: Lu, Jun, et al.
Publicado: (2021)

Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss
por: Liu, Shenghua, et al.
Publicado: (2016)

Erratum to “TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma”
Publicado: (2023)

Identification and Validation of Plasma Metabolomic Signatures in Precancerous Gastric Lesions That Progress to Cancer
por: Huang, Sha, et al.
Publicado: (2021)

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value
por: Lehmann, Brian David, et al.
Publicado: (2015)

Common activities and predictive gene signature identified for genetic hypomorphs of TP53
por: Leung, Jessica C., et al.
Publicado: (2023)

Identification and development of TP53 mutation-associated Long non-coding RNAs signature for optimized prognosis assessment and treatment selection in hepatocellular carcinoma
por: Chu, Chenghao, et al.
Publicado: (2023)

Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer
por: Zhang, Zhao, et al.
Publicado: (2022)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_56ohmb19cq1ih0mq84dgt0c05i